David Jorden
Chief Executive Officer at NUO THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
David Jorden active positions
Companies | Position | Start | End |
---|---|---|---|
NUO THERAPEUTICS, INC. | Director/Board Member | 2015-05-24 | - |
Chief Executive Officer | 2016-01-07 | - | |
Director of Finance/CFO | 2015-05-24 | - | |
Corporate Secretary | - | - | |
Chairman | 2012-02-06 | 2015-05-24 | |
Investor Relations Contact | 2008-09-30 | 2012-02-06 | |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Director/Board Member | 2013-05-31 | - |
Chief Executive Officer | 2013-05-31 | - |
Career history of David Jorden
Former positions of David Jorden
Companies | Position | Start | End |
---|---|---|---|
PLX PHARMA WINDDOWN CORP. | Director of Finance/CFO | 2015-05-31 | 2017-06-30 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Director/Board Member | 2008-08-11 | 2013-11-07 |
Director of Finance/CFO | 2012-08-13 | 2013-04-01 | |
MORGAN STANLEY | Corporate Officer/Principal | 2002-12-31 | - |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Director of Finance/CFO | 2000-02-29 | 2002-08-31 |
Fayez Sarofim & Co.
Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Corporate Officer/Principal | - | - |
PLx Pharma, Inc. /Old/
PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Director/Board Member | - | - |
Director of Finance/CFO | - | - |
Training of David Jorden
The University of Texas at Austin | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Statistics
International
United States | 11 |
Operational
Director of Finance/CFO | 5 |
Director/Board Member | 4 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 6 |
Finance | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
MORGAN STANLEY | Finance |
NUO THERAPEUTICS, INC. | Health Technology |
Private companies | 6 |
---|---|
Fayez Sarofim & Co.
Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Finance |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Commercial Services |
PLx Pharma, Inc. /Old/
PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
PLx Pharma, Inc.
PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
- Stock Market
- Insiders
- David Jorden
- Experience